PMID- 28991765
OWN - NLM
STAT- MEDLINE
DCOM- 20190701
LR  - 20211122
IS  - 1857-9345 (Print)
IS  - 1857-9345 (Linking)
VI  - 38
IP  - 2
DP  - 2017 Sep 1
TI  - Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia.
PG  - 123-129
LID - /j/prilozi.2017.38.issue-2/prilozi-2017-0030/prilozi-2017-0030.xml [pii]
LID - 10.1515/prilozi-2017-0030 [doi]
AB  - An increasing tendency has recently emerged for the use of phytotherapeutic 
      agents as alternative to commercial pharmacological agents for the treatment of 
      benign prostate hyperplasia (BPH). The purpose of this study is to evaluate the 
      effects of Serenoa repens alcohol extract treatment on BPH patients' symptoms and 
      major parameters during one-year follow-up. The study was performed on 70 men 
      aged 40 - 79 years (mean 60.58) with symptomatic BPH that were divided into a 
      group of 40 patients treated with Serenoa repens extract (SRT) and a control 
      group of 30 patients that received no treatment and were observed only. The 
      following parameters were determined at the time of diagnosis (baseline), and 
      after 6 and 12 months: prostate size, serum prostate-specific antigen (PSA) and 
      uroflowmetry parameters including maximum flow rate (MFR), average flow rate 
      (AFR) and post-voiding residual volume (PVRV). In addition, the relevant patient 
      symptoms were evaluated using the International Prostate Symptom Score (IPSS) 
      system. The patients in the SRT group showed a statistically significant 
      increment of the average MFR and AFR values and reduction of PV relative to the 
      control group (p<0.05). The significant differences between the proportion of 
      patients with prostate volume >40 ml in the SRE treated group vs. control group 
      was observed (p<0.05). The mean IPSS score was highly significantly reduced in 
      the SRT group (p<0.01). The mild improvements of the urine flow, prostate size 
      and IPSS score during 12 months treatment with the Serenoa repens extract 
      indicate possible efficiency of this phytotherapeutic agent in patients with BPH.
FAU - Saidi, Skender
AU  - Saidi S
AD  - .
FAU - Stavridis, Sotir
AU  - Stavridis S
AD  - .
FAU - Stankov, Oliver
AU  - Stankov O
AD  - .
FAU - Dohcev, Sasho
AU  - Dohcev S
AD  - .
FAU - Panov, Sasho
AU  - Panov S
AD  - .
LA  - eng
PT  - Clinical Study
PT  - Journal Article
PL  - North Macedonia
TA  - Pril (Makedon Akad Nauk Umet Odd Med Nauki)
JT  - Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski 
      nauki)
JID - 101677081
RN  - 0 (Alcohols)
RN  - 0 (Plant Extracts)
RN  - 0 (Solvents)
RN  - 0 (Urological Agents)
RN  - EC 3.4.21.- (KLK3 protein, human)
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - J7WWH9M8QS (saw palmetto extract)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alcohols/*chemistry
MH  - Case-Control Studies
MH  - Humans
MH  - Kallikreins/blood
MH  - Lower Urinary Tract Symptoms/blood/diagnosis/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts/adverse effects/isolation & purification/*therapeutic use
MH  - Prostate/diagnostic imaging/*drug effects/metabolism/physiopathology
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Hyperplasia/blood/diagnosis/*drug therapy/physiopathology
MH  - Republic of North Macedonia
MH  - Serenoa/*chemistry
MH  - Solvents/*chemistry
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ultrasonography
MH  - Urodynamics/drug effects
MH  - Urological Agents/adverse effects/isolation & purification/*therapeutic use
OTO - NOTNLM
OT  - Serenoa repens extract
OT  - benign prostate hyperplasia
OT  - phytotherapeutics
EDAT- 2017/10/11 06:00
MHDA- 2019/07/02 06:00
CRDT- 2017/10/10 06:00
PHST- 2017/10/10 06:00 [entrez]
PHST- 2017/10/11 06:00 [pubmed]
PHST- 2019/07/02 06:00 [medline]
AID - /j/prilozi.2017.38.issue-2/prilozi-2017-0030/prilozi-2017-0030.xml [pii]
AID - 10.1515/prilozi-2017-0030 [doi]
PST - ppublish
SO  - Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Sep 1;38(2):123-129. doi: 
      10.1515/prilozi-2017-0030.